Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
Posts
- Category: Wall Street Journal (continued)
- A.M. Vitals: Pfizer Arthritis Drug Improved Symptoms in Late-Stage Study
- A.M. Vitals: Pfizer CEO Ian Read Says There’s Life After Lipitor
- A.M. Vitals: Pfizer CEO Says Lipitor Share is As Expected
- A.M. Vitals: Pfizer Earnings Rise
- A.M. Vitals: Pfizer Earnings Rise 5.5% in Second Quarter
- A.M. Vitals: Pfizer Earnings Top Estimates, But Sales Miss
- A.M. Vitals: Pfizer Gets FDA Warning on Adverse Event Reporting
- A.M. Vitals: Pfizer Likely to Spin Off, Not Sell, Animal-Health Business
- A.M. Vitals: Pfizer Looking to Cut an Additional $1 Billion
- A.M. Vitals: Pfizer Looks to Extend Viagra Patent to 2019
- A.M. Vitals: Pfizer Plans to Sell Lipitor at Generic Prices Directly to Patients
- A.M. Vitals: Pfizer Says Arthritis Trial Had One Drug-Related Death
- A.M. Vitals: Pfizer Stops Some Drug Trials; No ‘Doc Fix’ Yet
- A.M. Vitals: Pfizer Waits for Approval to Conduct Embryonic Stem-Cell Trial
- A.M. Vitals: Pfizer, Medivation End Dimebon Development
- A.M. Vitals: Pfizer’s Chantix May Increase Risk For Heart Patients
- A.M. Vitals: Pfizer’s Drug Capsule Unit Fetches $2.38 Billion
- A.M. Vitals: Pfizer’s Read Keeps Key Leaders in Executive Shuffle
- A.M. Vitals: Pharma Companies Tapping Early-Stage Biotech Products
- A.M. Vitals: Pharma Pipelines Filling Up
- A.M. Vitals: Physicians React to Decisions on Glaxo’s Avandia
- A.M. Vitals: Pizza and cholesterol drugs, psychiatric meds and campaign promises
- A.M. Vitals: Pre-ASCO Studies on Drugs, Ovarian Cancer Screening
- A.M. Vitals: Prescription Painkillers Kill More People Than Heroin and Cocaine
- A.M. Vitals: Progress on Pinpointing Dangerous Prostate Cancers
- A.M. Vitals: Prostate-Cancer Drugs Improve Survival in Trials
- A.M. Vitals: Public Option is an Option in Debt Panel Draft Recommendations
- A.M. Vitals: Radiation Risk for Those Near Reactor in Japan
- A.M. Vitals: Ranbaxy Launches Generic Lipitor in U.S.
- A.M. Vitals: Rare Larynx Transplant Gives Calif. Woman Her Voice Back
- A.M. Vitals: Repeated Head Blows Associated With ALS-Like Condition
- A.M. Vitals: Republicans Still Support Ryan’s Medicare Plan After Defeat
- A.M. Vitals: Research Review Links Pfizer’s Chantix to Heart Problems
- A.M. Vitals: Research Suggests No Serious Heart Risk from ADHD Drugs
- A.M. Vitals: Retailers Promote Flu Shots
- A.M. Vitals: Roche Bets Big on Wider Use of Genetic Mapping
- A.M. Vitals: Roche Bids $5.7 Billion For Illumina
- A.M. Vitals: Roche Cancer Drugs Show Positive Results
- A.M. Vitals: Roche Gearing Up for Generic Battle
- A.M. Vitals: Roche Lowers Sales Forecast for Avastin
- A.M. Vitals: Roche Third-Quarter Sales Fell 7.3%
- A.M. Vitals: Roche Will Get Hearing on Avastin For Breast Cancer
- A.M. Vitals: Room For Compromise on Contraception Coverage?
- A.M. Vitals: Ryan, Wyden to Introduce Proposal for Changing Medicare
- A.M. Vitals: Salmonella-Tainted Ground Turkey Now Implicated in 107 Illnesses
- A.M. Vitals: Samsung Says Report Shows No Cancer Link to Factories
- A.M. Vitals: Sanofi (Again) Presses Genzyme to Talk
- A.M. Vitals: Sanofi Extends Offer for Genzyme; Few So Far Have Bitten
- A.M. Vitals: Sanofi Getting Financing Ready for Genzyme Bid
- A.M. Vitals: Sanofi Likely to Formally Offer to Buy Genzyme
- A.M. Vitals: Sanofi May Pay $74 Per Share Up Front for Genzyme
- A.M. Vitals: Sanofi Reports Breast Cancer Drug Setback
- A.M. Vitals: Sanofi Suggests Working Group to Look at Genzyme’s MS Drug
- A.M. Vitals: Sanofi, Genzyme Hope to (Finally) Ink Deal This Week
- A.M. Vitals: Sanofi, Genzyme Still Working on Deal Price
- A.M. Vitals: Sanofi’s 2011 Outlook Disappoints Investors
- A.M. Vitals: Scientists Stop or Delay Age-Related Diseases in Mice
- A.M. Vitals: Searching for the Source of Lung Cancer in Women
- A.M. Vitals: Secrecy in Medicare
- A.M. Vitals: Senate May Vote on Health-Care Law Repeal
- A.M. Vitals: Senators Push for Brand-Name-Friendly Biologics Policy
- A.M. Vitals: Side Effects Sideline Roche’s Experimental Diabetes Drug
- A.M. Vitals: Silicone Breast Implants Carry Risks, But Will Stay on the Market
- A.M. Vitals: Six Health-Care IPOs Planned For This Week
- A.M. Vitals: Slow Economy, Government Cuts Squeeze Nonprofit Hospitals
- A.M. Vitals: So Far, Radiation Risk in Japan is Low
- A.M. Vitals: Social Media Helped Fuel Protests Against Komen
- A.M. Vitals: Some Angioplasties Aren’t Necessary, Study Says
- A.M. Vitals: Some Japanese Food Shipments Suspended on Radiation Fears
- A.M. Vitals: St. Jude Medical Will Pay About $1.1 Billion for AGA Medical
- A.M. Vitals: Standing for Plaintiff in Health-Law Suit May Be in Question
- A.M. Vitals: States Can Decide on Essential Benefits for Health Plans
- A.M. Vitals: Statin Use Associated With Lower Risk of Prostate-Cancer Death
- A.M. Vitals: Study Highlights Value of Less Invasive Breast Cancer Treatments
- A.M. Vitals: Study Questions Genetic Test for Plavix
2009 -